Lazard Capital Starts Endologix (ELGX) at Buy
More News related to ELGX
- Endologix to Present at Three Upcoming Conferences
- Endologix (ELGX) Tops Q3 EPS by 1c; Guides In-line
- Endologix Reports 47% Third Quarter 2009 Revenue Growth
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
- Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
More News related to New Coverage
- HSBC Starts PWRD at Overweight, SNDA, NTES at Neutral
- Macquarie Initiates Coverage on Deere & Co (DE) with a Neutral
- MKM Partners Initiates Coverage on Hertz Global (HTZ) & Avis Budget Group (CAR)
- Jefferies & Co Initiates Coverage on Mettler-Toledo (MTD) with a Buy
- Jefferies & Co Initiates Coverage on Millipore (MIL) with a Buy
Lazard Capital initiates coverage on Endologix (Nasdaq: ELGX) with a Buy rating and $6 price target.
Endologix, Inc. engages in the development, manufacture, marketing, and sale of minimally invasive therapies for the treatment of vascular diseases.
Related Categories
New CoverageStocks Mentioned
-0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
